title: Antithrombotic therapy in obesity.
abstract: Clinical management of obese subjects to reduce their risk of suffering cardiovascular events is complex. Obese patients typically require preventive strategies, life-style modifications, and multi-drug therapy to address obesity-induced co-morbidities. Data regarding the effects of excess weight on the pharmacokinetics of most drugs is scarce as these individuals are often excluded from clinical trials. However, the physiological alterations observed in obese patients and their lower response to some antiplatelet agents and anticoagulants have suggested that dosage regimes need to be adjusted for these subjects. In this review we will briefly discuss platelet alterations that can contribute to increased thrombotic risk, analyse existing data regarding the effects of obesity on drug pharmacokinetics focusing on antiplatelet agents and anticoagulants, and we will describe the beneficial effects of weight loss on thrombosis.
authors.affiliation: Prof. Lina Badimon, Cardiovascular Research Center, C/ Sant Antoni Mª Claret 167, 08025 Barcelona, Spain, Tel.: +34 93 556 58 80, Fax: +34 93 556 55 59, E-mail: lbadimon@csic-iccc.org.
authors.forename: Lina
authors.initials: L
authors.lastname: Badimon
authors.forename: Rodrigo
authors.initials: R
authors.lastname: Hernández Vera
authors.forename: Teresa
authors.initials: T
authors.lastname: Padró
authors.forename: Gemma
authors.initials: G
authors.lastname: Vilahur
mesh_terms: D000818:Animals; D001792:Blood Platelets / Q000187:drug effects* / Q000378:metabolism; D054796:Drug Dosage Calculations; D005343:Fibrinolytic Agents / Q000493:pharmacokinetics / Q000627:therapeutic use*; D006801:Humans; D009765:Obesity / Q000503:physiopathology / Q000628:therapy*; D015539:Platelet Activation / Q000187:drug effects; D012306:Risk; D013927:Thrombosis / Q000503:physiopathology / Q000628:therapy*; D015431:Weight Loss
chemical_list: D005343:Fibrinolytic Agents
keywords: Obesity; anticoagulants; antiplatelets